These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

720 related articles for article (PubMed ID: 33720308)

  • 1. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
    Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
    JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitor-associated central nervous system autoimmunity.
    Valencia-Sanchez C; Sechi E; Dubey D; Flanagan EP; McKeon A; Pittock SJ; Zekeridou A
    Eur J Neurol; 2023 Aug; 30(8):2418-2429. PubMed ID: 37151179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.
    Vogrig A; Fouret M; Joubert B; Picard G; Rogemond V; Pinto AL; Muñiz-Castrillo S; Roger M; Raimbourg J; Dayen C; Grignou L; Pallix-Guyot M; Lannoy J; Ducray F; Desestret V; Psimaras D; Honnorat J
    Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31454760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.
    Müller-Jensen L; Zierold S; Versluis JM; Boehmerle W; Huehnchen P; Endres M; Mohr R; Compter A; Blank CU; Hagenacker T; Meier F; Reinhardt L; Gesierich A; Salzmann M; Hassel JC; Ugurel S; Zimmer L; Banks P; Spain L; Soon JA; Enokida T; Tahara M; Kähler KC; Seggewiss-Bernhardt R; Harvey C; Long GV; Schöberl F; von Baumgarten L; Hundsberger T; Schlaak M; French LE; Knauss S; Heinzerling LM
    Eur J Cancer; 2022 Nov; 175():224-235. PubMed ID: 36155116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system complications associated with immune checkpoint inhibitors.
    Vogrig A; Muñiz-Castrillo S; Joubert B; Picard G; Rogemond V; Marchal C; Chiappa AM; Chanson E; Skowron F; Leblanc A; Ducray F; Honnorat J
    J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):772-778. PubMed ID: 32312871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
    Purde MT; Niederer R; Wagner NB; Diem S; Berner F; Hasan Ali O; Hillmann D; Bergamin I; Joerger M; Risch M; Niederhauser C; Lenz TL; Früh M; Risch L; Semela D; Flatz L
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):647-656. PubMed ID: 34874490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature.
    Stuby J; Herren T; Schwegler Naumburger G; Papet C; Rudiger A
    Swiss Med Wkly; 2020 Nov; 150():w20377. PubMed ID: 33232507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes.
    Yabuki S; Hirai H; Moriya C; Kusano Y; Hasegawa T
    Front Endocrinol (Lausanne); 2024; 15():1407192. PubMed ID: 38841300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysautonomia associated with immune checkpoint inhibitors.
    Tezuka T; Okuzumi S; Nakashima C; Ide T; Imai S; Mitsuboshi S; Kuwahara Y; Takizawa T; Seki M; Minematsu N; Aragane N; Nakahara J; Hori S; Nakane S; Suzuki S
    J Neurol; 2023 Jul; 270(7):3413-3423. PubMed ID: 36939931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond T cell toxicity - Intrathecal chemokine CXCL13 indicating B cell involvement in immune-related adverse events following checkpoint inhibition: A two-case series and literature review.
    Otto F; Seiberl M; Bieler L; Moser T; Kleindienst W; Wallner-Essl W; Koelblinger P; Wipfler P; Harrer A
    Eur J Neurol; 2024 Jul; 31(7):e16279. PubMed ID: 38556899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
    Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
    Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between immune-related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis.
    Euvrard R; Robert M; Mainbourg S; Dalle S; Lega JC
    Fundam Clin Pharmacol; 2024 Apr; 38(2):369-379. PubMed ID: 38012082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
    Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotoxicities associated with immune checkpoint inhibitor therapy.
    Duong SL; Barbiero FJ; Nowak RJ; Baehring JM
    J Neurooncol; 2021 Apr; 152(2):265-277. PubMed ID: 33454891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study.
    Farina A; Villagrán-García M; Fourier A; Pinto AL; Chorfa F; Timestit N; Alberto T; Aupy J; Benaiteau M; Birzu C; Campetella L; Cotton F; Dalle S; Delaruelle CF; Dumez P; Germi R; Le Maréchal M; Maillet D; Marignier R; Pegat A; Psimaras D; Rafiq M; Picard G; Desestret V; Quadrio I; Honnorat J; Joubert B
    Lancet Reg Health Eur; 2024 Sep; 44():101011. PubMed ID: 39170102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis.
    Isidro RA; Ruan AB; Gannarapu S; Raj D; Rahma O; Grover S; Srivastava A
    Histopathology; 2021 Mar; 78(4):532-541. PubMed ID: 32931028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament light chain levels reflect outcome in a patient with glutamic acid decarboxylase 65 antibody-positive autoimmune encephalitis under immune checkpoint inhibitor therapy.
    Piepgras J; Müller A; Steffen F; Lotz J; Loquai C; Zipp F; Dresel C; Bittner S
    Eur J Neurol; 2021 Mar; 28(3):1086-1089. PubMed ID: 33556229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis.
    Guo Q; Gao J; Guo H; Xie J; Cheng J
    Int Immunopharmacol; 2023 Jan; 114():109490. PubMed ID: 36459923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebellar involvement associated with immune checkpoint inhibitors: A systematic review.
    Dinoto A; Mantovani E; Ferrari S; Mariotto S; Tamburin S
    Eur J Neurol; 2023 Mar; 30(3):774-781. PubMed ID: 36325694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.